Rare LPL gene variants attenuate triglyceride reduction and HDL cholesterol increase in response to fenofibric acid therapy in individuals with mixed dyslipidemia

Atherosclerosis

Volumn 234, Issue 2, 2014, Pages 249-253

  Gao, Feng ^a   Ballantyne, Christie ^b,c   Ma, Li ^a,d   Virani, Salim S ^b,c,e   Keinan, Alon ^a   Brautbar, Ariel ^b,c,f  

^a Program on Infrastructure Policy   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF MARYLAND   (United States)

^e MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f MARSHFIELD CLINIC   (United States)

Author keywords

Dyslipidemia; Fenofibric acid; High density lipoprotein cholesterol; LPL gene variants

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN C2; APOLIPOPROTEIN C3; ATORVASTATIN; FENOFIBRIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; ANTILIPEMIC AGENT; APOB PROTEIN, HUMAN; APOLIPOPROTEIN B100; BIOLOGICAL MARKER; FENOFIBRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN LIPASE; LPL PROTEIN, HUMAN;

ARTICLE; BODY MASS; CONTROLLED STUDY; CORONARY RISK; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; DYSLIPIDEMIA; FEMALE; GENE FREQUENCY; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; BLOOD; COMBINATION DRUG THERAPY; DYSLIPIDEMIAS; GENETIC PREDISPOSITION; GENETIC VARIATION; GENETICS; PHARMACOGENETICS; PROSPECTIVE STUDY; TREATMENT OUTCOME;

APOLIPOPROTEIN B-100; APOLIPOPROTEIN C-III; BIOMARKERS; CHOLESTEROL, HDL; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; FEMALE; FENOFIBRATE; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; LIPOPROTEIN LIPASE; MALE; PHARMACOGENETICS; PHENOTYPE; PROSPECTIVE STUDIES; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 84900848819     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.03.010     Document Type: Article

References (22)

1. Lai C.Q., Arnett D.K., Corella D., et al. Fenofibrate effect on triglyceride and postprandial response of apolipoprotein A5 variants: the GOLDN study. Arterioscler Thromb Vasc Biol 2007, 27:1417-1425.
2. Brautbar A., Covarrubias D., Belmont J., et al. Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia. Atherosclerosis 2011, 219:737-742.
3. Brautbar A., Virani S.S., Belmont J., et al. LPL gene variants affect apoC-III response to combination therapy of statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia. JLipid Res 2012, 53:556-560.
4. Ma L., Ballantyne C.M., Belmont J.W., Keinan A., Brautbar A. Interaction between SNPs in the RXRA and near ANGPTL3 gene region inhibits apoB reduction after statin-fenofibric acid therapy in individuals with mixed dyslipidemia. JLipid Res 2012, 53:2425-2428.
5. Cardona F., Guardiola M., Queipo-Ortuño M.I., Murri M., Ribalta J., Tinahones F.J. The -1131T>C SNP of the APOA5 gene modulates response to fenofibrate treatment in patients with the metabolic syndrome: a postprandial study. Atherosclerosis 2009, 206:148-152.
6. Liu Y., Ordovas J.M., Gao G., et al. Pharmacogenetic association of the APOA1/C3/A4/A5 gene cluster and lipid responses to fenofibrate: the genetics of lipid-lowering drugs and diet network study. Pharmacogenet Genomics 2009, 19:161-169.
7. Chien K.L., Lin Y.L., Wen H.C., et al. Common sequence variant in lipoprotein lipase gene conferring triglyceride response to fibrate treatment. Pharmacogenomics 2009, 10:267-276.
8. Cohen J.C., Kiss R.S., Pertsemlidis A., et al. Multiple rare alleles contribute to low plasma levels of HDL cholesterol. Science 2004, 305:869-872.
9. Cohen J.C., Boerwinkle E., Mosley T.H., et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. NEngl J Med 2006, 354:1264-1272.
10. Brautbar A., Barbalic M., Chen F., et al. Rare APOA5 promoter variants associated with paradoxical HDL cholesterol decrease in response to fenofibric acid therapy. JLipid Res 2013, 54:1980-1987.
11. Jones P.H., Bays H.E., Davidson M.H., et al. Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins: study design and rationale of a phase III clinical programme. Clin Drug Investig 2008, 28:625-634.
12. Jones P.H., Davidson M.H., Kashyap M.L., et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study. Atherosclerosis 2009, 204:208-215.
13. Zhang J., Wheeler D.A., Yakub I., et al. SNPdetector: a software tool for sensitive and accurate SNP detection. PLoS Comput Biol 2005, 1:e53.
14. Wu M.C., Lee S., Cai T., Li Y., Boehnke M., Lin X. Rare-variant association testing for sequencing data with the sequence kernel association test. Am J Hum Genet 2011, 89:82-93.
15. Morgenthaler S., Thilly W.G. Astrategy to discover genes that carry multi-allelic or mono-allelic risk for common diseases: a cohort allelic sums test (CAST). Mutat Res 2007, 615:28-56.
16. Li B., Leal S.M. Methods for detecting associations with rare variants for common diseases: application to analysis of sequence data. Am J Hum Genet 2008, 83:311-321.
17. Morris A.P., Zeggini E. An evaluation of statistical approaches to rare variant analysis in genetic association studies. Genet Epidemiol 2010, 34:188-193.
18. R: a language and environment for statistical computing 2012, R Development Core Team, R Foundation for Statistical Computing, Vienna, Austria, ISBN 3-900051-07-0. Available at:. http://www.R-project.org/.
19. Sarwar N., Sandhu M.S., et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 2010, 375:1634-1639. Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration.
20. Ginsbert H.N., Elam M.B., et al. Effects of combination lipid therapy in type 2 diabetes mellitus. NEngl J Med 2010, 362:1563-1574. ACCORD Study Group.
21. Johansen C.T., Hegele R.A. Genetic bases of hypertriglyceridemic phenotypes. Curr Opin Lipidol 2011, 22:247-253.
22. van Raalte D.H., Li M., Pritchard P.H., Wasan K.M. Peroxisome proliferator-activated receptor (PPAR)-alpha: a pharmacological target with a promising future. Pharm Res 2004, 21:1531-1538.